http://www.fpnotebook.com/
Sitagliptin
Aka: Sitagliptin, Januvia, DPP-4 Inhibitor, Dipeptidyl Peptidase-4 Inhibitor, DPP-4, Gliptin
- See Also
- Incretin Mimetic
- Byetta
- Indications
- Type II Diabetes Mellitus
- Insulin deficiency and Insulin Resistance
- Adjunct to Glucophage, Sulfonylureas, Glitazones
- Contraindications
- Type I Diabetes Mellitus
- Concurrent Insulin use
- Prior history of malignancy
- Due to increased risk of cancer invasion and metastases
- Women of child bearing age (relative contraindication)
- Teratogenicity risk
- Adverse Effects
- Acute Pancreatitis
- Incidence may be as high as 1 in 50 for two years
- Singh (2013) JAMA Intern Med 173(7):534-9
- Serious Allergic Reaction (Sitagliptin)
- Anaphylaxis
- Angioedema
- Hepatotoxicity (Vildagliptin)
- Mechanism
- Blocks Dipeptidyl Peptidase-4 Inhibitor (DPP-4) allowing 2-3x accumulation of GLP-1
- Differs from Byetta: Weight neutral, no Nausea
- Dosing: Sitagliptin
- May be dosed with or without food
- Standard dosing
- Creatinine Clearance >50 ml/min: 100 mg once daily
- Renal insufficiency
- Consider Tradjenda instead, as does not require Renal Dosing adjustment
- Creatinine Clearance 30-49 ml/min: 50 mg once daily
- Creatinine Clearance <30 ml/min: 25 mg once daily
- Efficacy
- Lowers HBA1C 0.6%
- References
- Jones (2007) Am Fam Physician 75:1831-5